2020
DOI: 10.1186/s12889-020-09967-w
|View full text |Cite
|
Sign up to set email alerts
|

Socioeconomic inequality in intermittent preventive treatment using Sulphadoxine pyrimethamine among pregnant women in Nigeria

Abstract: Background Intermittent preventive treatment using Sulphadoxine pyrimethamine (IPTp-SP) for malaria prevention is recommended for all pregnant women in malaria endemic areas. However, there is limited evidence on the level of socioeconomic inequality in IPTp-SP use among pregnant women in Nigeria. Thus, this study aimed to determine the level of socioeconomic inequality in IPTp-SP use among pregnant women in Nigeria and to decompose it into its contributing factors. … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
13
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(17 citation statements)
references
References 25 publications
3
13
1
Order By: Relevance
“…The study found that the realised usage of optimal doses of IPTp among women with recent deliveries in Nigeria is low (21.8%). This is consistent with evidence provided in government reports [7] and several hospital or population-based studies [25,9,11,20,13]. However, the observed prevalence deviates widely from ndings in few other studies [18,23,22,19,14].…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…The study found that the realised usage of optimal doses of IPTp among women with recent deliveries in Nigeria is low (21.8%). This is consistent with evidence provided in government reports [7] and several hospital or population-based studies [25,9,11,20,13]. However, the observed prevalence deviates widely from ndings in few other studies [18,23,22,19,14].…”
Section: Discussionsupporting
confidence: 91%
“…This is important because low coverage re ects missed opportunities not only to deliver IPTp to pregnant women [16] but also missed opportunities to reduce adverse maternal and child health outcomes [17] in the country. Studies in Nigeria [18][19][20]12] and elsewhere in sub-Saharan Africa [13][14] have explored the factors in uencing use of IPTp with many of the studies identifying some important determinants of IPTp usage across sub-Saharan Africa. The identi ed determinants among others include type of antenatal care facility, health insurance enrolment, number of antenatal care visits [21], education, parity [22], timing of rst antenatal visit [23], employment [24], place of residence [25], geographical region [13], knowledge of malaria preventive strategies [26], maternal age, and household wealth index [27][28].…”
Section: Introductionmentioning
confidence: 99%
“…However, this current study found that pregnant women have reduced odds of receiving the optimal doses of IPTp-SP regardless of their wealth index. Conversely, Muhammed et al, 2020 found that pregnant women from the wealthiest households have increased IPTp-SP uptake than those from the poorest households in Nigeria (11). The disparity in the results may be attributed to the different methodologies adopted in assessing the association between wealth index and uptake of IPTp-SP.…”
Section: Discussionmentioning
confidence: 99%
“…Studies have reported that pregnant women’s attitudes and motivation to receive IPTp-SP was related to their levels of knowledge of malaria-related factors such as morbidities caused by malaria (8, 9). Similarly, region, religion, age, and marital status influenced the number IPTp-SP doses received during pregnancy (8,10,11). Socioeconomic considerations including education level, spouse’s education level, employment status, health insurance coverage and household wealth index influenced IPTp-SP uptake (12, 13).…”
Section: Introductionmentioning
confidence: 99%
“…One of these recommendations is to protect pregnant women with SP antimalarial drug in regions where there are moderate and high transmission of malaria [11]. In Nigeria, only 26.2% of pregnant women took three doses or more of IPTp as recommended by the WHO [12].…”
Section: Introductionmentioning
confidence: 99%